Sector: Health Care
Director information for NEUROCRINE BIOSCIENCES INC (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Andrew Ratz, Ph.D. | Chief Technical Operations Officer | 58 | [] | [] | 2026 |
| Christine A. Poon | Director | 73 | ["Commercial Strategy/Market Access","Healthcare Industry","Biotech and Pharma Operations Expertise","M&A/Business Development Transactions","Governance","Investor Relations","Public Policy","Executive Leadership"] | ["Compensation","Science and Medical Technology"] | 2026 |
| Gary A. Lyons | ["Financial Expertise / Capital Management and Allocation","Commercial Strategy/Market Access","Drug Development","Healthcare Industry","Biotech and Pharma Operations Expertise","M&A/Business Development Transactions","Governance","Investor Relations","Executive Leadership","Risk Management Oversight","Human Capital Management"] | ["Audit","Compensation","Nominating /Corporate Governance","Science and Medical Technology"] | 2026 | ||
| George J. Morrow | Director | 74 | ["Financial Expertise / Capital Management and Allocation","Commercial Strategy/Market Access","Drug Development","Healthcare Industry","Biotech and Pharma Operations Expertise","M&A/Business Development Transactions","Governance","Investor Relations","Executive Leadership","Risk Management Oversight"] | ["Compensation","Science and Medical Technology"] | 2026 |
| Johanna Mercier | ["Commercial Strategy/Market Access","Healthcare Industry","Biotech and Pharma Operations Expertise","M&A/Business Development Transactions","Governance","Investor Relations","Executive Leadership","Human Capital Management"] | ["Audit","Compensation","Nominating /Corporate Governance","Science and Medical Technology"] | 2026 | ||
| Kevin C. Gorman, Ph.D. | [] | ["Audit","Compensation","Nominating /Corporate Governance","Science and Medical Technology"] | 2026 | ||
| Kevin Gorman, Ph.D. | ["Financial Expertise / Capital Management and Allocation","Commercial Strategy/Market Access","Science and Medicine","Drug Development","Healthcare Industry","Biotech and Pharma Operations Expertise","M&A/Business Development Transactions","Governance","Investor Relations","Global Business Operations","Public Policy","Executive Leadership","Risk Management Oversight","Human Capital Management"] | [] | 2026 | ||
| Kyle Gano, Ph.D. | ["Financial Expertise / Capital Management and Allocation","Drug Development","Healthcare Industry","Biotech and Pharma Operations Expertise","Governance","Investor Relations","Executive Leadership","Human Capital Management"] | [] | 2026 | ||
| Kyle W. Gano, Ph.D. | Chief Executive Officer and Director | 53 | [] | [] | 2026 |
| Leslie V. Norwalk | Director | 60 | ["Healthcare Industry","Biotech and Pharma Operations Expertise","Governance","Investor Relations","Public Policy","Executive Leadership"] | ["Nominating /Corporate Governance"] | 2026 |
| Richard F. Pops | Director | 64 | ["Financial Expertise / Capital Management and Allocation","Commercial Strategy/Market Access","Healthcare Industry","Biotech and Pharma Operations Expertise","M&A/Business Development Transactions","Governance","Investor Relations","Executive Leadership","Risk Management Oversight"] | ["Audit","Compensation"] | 2026 |
| Shalini Sharp | Director | 51 | ["Healthcare Industry","Governance","Investor Relations","Executive Leadership"] | ["Nominating /Corporate Governance"] | 2026 |
| Stephen A. Sherwin, M.D. | Director | 77 | [] | ["Science and Medical Technology"] | 2026 |
| Stephen Sherwin, M.D. | ["Financial Expertise / Capital Management and Allocation","Drug Development","Healthcare Industry","Biotech and Pharma Operations Expertise","Governance","Investor Relations","Executive Leadership","Risk Management Oversight"] | [] | 2026 | ||
| William H. Rastetter, Ph.D. | Board Chair; Chairman of the Board | 77 | [] | ["Audit","Compensation","Nominating /Corporate Governance","Science and Medical Technology"] | 2026 |
| William Rastetter, Ph.D. | ["Financial Expertise / Capital Management and Allocation","Commercial Strategy/Market Access","Drug Development","Healthcare Industry","Biotech and Pharma Operations Expertise","M&A/Business Development Transactions","Governance","Investor Relations","Public Policy","Executive Leadership","Risk Management Oversight"] | [] | 2026 |
